Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis

doi:10.4240/wjgs.v16.i1.228

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1037)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

557

Figures (1-3)

Tables (1-2)

Sum=755

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

176

Sum=238

Jan 27, 2024 (publication date) through May 20, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Surg. Jan 27, 2024; 16(1): 228-238
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.228

Open in New Tab Full Size Figure Download Figure

Figure 1 A flowchart of study screening and selection process. OSM: Oncostatin M; IBD: Inflammatory bowel disease.

Open in New Tab Full Size Figure Download Figure

Figure 2 A forest graph showing the outcomes of a meta-analysis of standardized mean differences between responders and non-responders, remitters and non-remitters, and mucosal healers and non-healers of anti-tumor necrosis factor-based therapies in patients with inflammatory bowel disease. OSM: Oncostatin M; TNF: Tumor necrosis factor; SMD: Standardized mean difference.

Open in New Tab Full Size Figure Download Figure

Figure 3 A forest graph showing the outcomes of a meta-analysis of correlation coefficients between baseline Oncostatin M and other baseline inflammatory biomarkers/disease indicators. OSM: Oncostatin M; TNF: Tumor necrosis factor.

Citation: Yang Y, Fu KZ, Pan G. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis. World J Gastrointest Surg 2024; 16(1): 228-238
URL: https://www.wjgnet.com/1948-9366/full/v16/i1/228.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i1.228